NO20080176L - PARP-modulatorer og behandling av kreft - Google Patents

PARP-modulatorer og behandling av kreft

Info

Publication number: NO20080176L
Authority: NO; Norway
Prior art keywords: parp; activity; aromatic compound; organic aromatic; mammal
Prior art date: 2005-06-10

Application number

NO20080176A

Other languages

English (en)

Norwegian (no)

Inventor

Ernest Kun

Jerome Mendeleyev

Pal Bauer

Original Assignee

Bipar Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-10

Filing date

2008-01-10

Publication date

2008-03-10

2008-01-10 Application filed by Bipar Sciences Inc filed Critical Bipar Sciences Inc

2008-03-10 Publication of NO20080176L publication Critical patent/NO20080176L/no

Links

229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
150000001491 aromatic compounds Chemical class 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 abstract 1
101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
150000008375 benzopyrones Chemical class 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000002091 cationic group Chemical group 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 abstract 1
150000002475 indoles Chemical class 0.000 abstract 1
150000003951 lactams Chemical group 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/10—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring unsubstituted
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Addiction (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)

NO20080176A 2005-06-10 2008-01-10 PARP-modulatorer og behandling av kreft NO20080176L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68917805P	2005-06-10	2005-06-10
PCT/US2006/022907 WO2006135873A2 (fr)	2005-06-10	2006-06-12	Modulateurs de parp et traitement du cancer

Publications (1)

Publication Number	Publication Date
NO20080176L true NO20080176L (no)	2008-03-10

Family

ID=37532884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20080176A NO20080176L (no)	2005-06-10	2008-01-10	PARP-modulatorer og behandling av kreft

Country Status (13)

Country	Link
US (2)	US20070015814A1 (fr)
EP (1)	EP1904468A4 (fr)
JP (1)	JP2008543786A (fr)
KR (1)	KR20080031266A (fr)
CN (1)	CN101233121A (fr)
AU (1)	AU2006257815A1 (fr)
BR (1)	BRPI0611814A2 (fr)
CA (1)	CA2612979A1 (fr)
IL (1)	IL187898A0 (fr)
MX (1)	MX2007015479A (fr)
NO (1)	NO20080176L (fr)
RU (1)	RU2008100017A (fr)
WO (1)	WO2006135873A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7961081B2 (en) *	2003-05-22	2011-06-14	John Tomlienovic	Anti-theft system and method
CN101233121A (zh) *	2005-06-10	2008-07-30	彼帕科学公司	Parp调节剂和癌症的治疗
ZA200800907B (en)	2005-07-18	2010-04-28	Bipar Sciences Inc	Treatment of cancer
US20090029966A1 (en) *	2006-01-17	2009-01-29	Abbott Laboratories	Combination therapy with parp inhibitors
US20080146638A1 (en) *	2006-01-17	2008-06-19	Abbott Laboratories	Combination therapy with parp inhibitors
US20080280867A1 (en) *	2006-01-17	2008-11-13	Abbott Laboratories	Combination therapy with parp inhibitors
EP1976515A2 (fr) *	2006-01-17	2008-10-08	Abbott Laboratories	Polythérapie faisant appel à des inhibiteurs de la parp
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
JP2010504079A (ja) *	2006-06-12	2010-02-12	バイパーサイエンシズ，インコーポレイティド	Ｐａｒｐ阻害剤を用いる疾病の治療方法
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US20100160442A1 (en) *	2006-07-18	2010-06-24	Ossovskaya Valeria S	Formulations for cancer treatment
CN101534836B (zh)	2006-09-05	2011-09-28	彼帕科学公司	Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Traitement du cancer
WO2008030892A2 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Concept de médicament pour inhibiteurs de tubuline, compositions et procédés de traitement
WO2008030887A2 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Procédés de conception d'inhibiteurs de parp et leurs utilisations
EP2121139B1 (fr) *	2007-01-16	2012-10-10	BiPar Sciences, Inc.	Préparations pour le traitement du cancer
CN101903025A (zh) *	2007-10-19	2010-12-01	彼帕科学公司	利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
US7732491B2 (en) *	2007-11-12	2010-06-08	Bipar Sciences, Inc.	Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2217244A4 (fr) *	2007-11-12	2011-08-31	Bipar Sciences Inc	Traitement du cancer de l'utérus et du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
RU2010128107A (ru) *	2007-12-07	2012-01-20	Байпар Сайенсиз, Инк. (Us)	Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
MX2010008572A (es) *	2008-02-04	2010-11-30	Bipar Sciences Inc	Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
CN103214470A (zh) *	2012-01-18	2013-07-24	杨更亮	酮类与吲哚衍生物反应合成的新型抗癌化合物
CN107998127B (zh) *	2015-04-08	2020-07-03	华中科技大学	2h-1-苯并吡喃-2-酮在制备抑制淋巴细胞增殖药物中的应用
AU2016296905B2 (en)	2015-07-23	2018-07-05	Centre National De La Recherche Scientifique	Use of a combination of Dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en)	2015-11-05	2015-12-23	King S College London	Combination
SG10201609131YA (en) *	2016-11-01	2018-06-28	Xylonix Ip Holdings Pte Ltd	Zinc-pga compositions and methods for treating cancer
WO2018162439A1 (fr)	2017-03-08	2018-09-13	Onxeo	Nouveau biomarqueur prédictif de la sensibilité à un traitement du cancer avec une molécule dbait
US11433074B2 (en)	2017-06-22	2022-09-06	Triact Therapeutics, Inc.	Methods of treating glioblastoma
EP3687501A4 (fr)	2017-09-29	2021-06-23	Triact Therapeutics, Inc.	Formulations d'iniparib et leurs utilisations
CA3092779A1 (fr)	2018-03-13	2019-09-19	Onxeo	Molecule dbait contre la resistance acquise dans le traitement du cancer
BR122022012697B1 (pt)	2018-07-10	2023-04-04	Novartis Ag	Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
CN114053276B (zh) *	2020-07-30	2024-05-07	江苏天士力帝益药业有限公司	一种parp抑制剂tsl-1502中间体tsl-1502m的用途
CN121398822A (zh)	2023-06-21	2026-01-23	四方生物科学有限公司	用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2056790T3 (es) *	1986-01-17	1994-10-16	Preventive Medicine Inst	Ensayo para determinar la predisposicion o susceptibilidad a enfermedades asociadas con dna.
CA1326108C (fr) *	1988-04-12	1994-01-11	Sun Hyuk Kim	Antagoniste de la cck
US5177075A (en) *	1988-08-19	1993-01-05	Warner-Lambert Company	Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
WO1991004663A1 (fr) *	1989-09-26	1991-04-18	The Regents Of The University Of California	6-amino-1,2-benzopyrones utiles dans le traitement de maladies virales
US5633282A (en) *	1990-05-25	1997-05-27	British Technology Group Limited	Inhibition of viral infection
US5232735A (en) *	1990-06-01	1993-08-03	Bioresearch, Inc.	Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5637618A (en) *	1990-06-01	1997-06-10	Bioresearch, Inc.	Specific eatable taste modifiers
US5631038A (en) *	1990-06-01	1997-05-20	Bioresearch, Inc.	Specific eatable taste modifiers
US5484951A (en) *	1990-10-19	1996-01-16	Octamer, Incorporated	5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
FR2680366B1 (fr) *	1991-08-13	1995-01-20	Adir	Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5473074A (en) *	1991-10-22	1995-12-05	Octamer, Incorporated	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5464871A (en) *	1993-05-12	1995-11-07	Octamer, Inc.	Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) *	1991-10-22	1996-01-09	Octamer, Inc.	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5753674A (en) *	1991-10-22	1998-05-19	Octamer, Inc.	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5877185A (en) *	1991-10-22	1999-03-02	Octamer, Inc.	Synergistic compositions useful as anti-tumor agents
US5516941A (en) *	1991-10-22	1996-05-14	Octamer, Inc.	Specific inactivators of "retroviral" (asymmetric) zinc fingers
JP3070767B2 (ja) *	1991-10-22	2000-07-31	オクタマー，インコーポレイティド	抗腫瘍及び抗―レトロウィルス剤として有用なアデノシンジホスホリボースポリメラーゼ結合性ニトロソ芳香族化合物
US6008250A (en) *	1993-05-26	1999-12-28	Bioresearch, Inc.	Specific eatable taste modifiers
US6015792A (en) *	1993-05-26	2000-01-18	Bioresearch, Inc.	Specific eatable taste modifiers
GB9404485D0 (en) *	1994-03-09	1994-04-20	Cancer Res Campaign Tech	Benzamide analogues
US5589483A (en) *	1994-12-21	1996-12-31	Geron Corporation	Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
SK77598A3 (en) *	1995-12-14	1999-01-11	Merck & Co Inc	Nonpeptide derivatives, pharmaceutical composition containing them and their use
US5837729A (en) *	1996-04-26	1998-11-17	Metatron, Inc.	Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
AU7484798A (en) *	1997-05-13	1998-12-08	Octamer, Inc.	Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors
US5908861A (en) *	1997-05-13	1999-06-01	Octamer, Inc.	Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
ZA994406B (en) *	1998-03-04	2000-02-11	Searle & Co	Meta-azacyclic amino benzoic acid and derivatives thereof.
CN1079395C (zh) *	1998-03-18	2002-02-20	谭敦宪	N－乙酰－5,6－二甲氧基色胺的生产方法
TR200101498T2 (tr) *	1998-11-27	2001-11-21	Basf Aktiengesellschaft	İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
US6423696B1 (en) *	1999-04-16	2002-07-23	The United States Of America, As Represented By The Department Of Health & Human Services	Inhibition of arylamine N-acetyl transferase
US6451602B1 (en) *	2000-03-02	2002-09-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PARP expression
IL138825A (en) *	2000-10-03	2006-06-11	Neurim Pharma 1991	Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
US20020164633A1 (en) *	2001-04-20	2002-11-07	Inotek Pharmaceuticals Corporation	Cell-based assay for detecting activation of poly (ADP-ribose) polymerase
WO2002090334A1 (fr) *	2001-05-08	2002-11-14	Kudos Pharmaceuticals Limited	Derives d'isoquinolinone comme inhibiteurs de parp
US20050113283A1 (en) *	2002-01-18	2005-05-26	David Solow-Cordero	Methods of treating conditions associated with an EDG-4 receptor
EP1597233A1 (fr) *	2003-02-11	2005-11-23	Warner-Lambert Company LLC	Derives de benzyluree et de thiouree utiles en tant qu'antagonistes des androgenes
WO2005023765A1 (fr) *	2003-09-11	2005-03-17	Pharmacia & Upjohn Company Llc	Methode de catalyse de reactions d'amidation au moyen de co2
PL2305221T3 (pl) *	2003-12-01	2015-11-30	Kudos Pharm Ltd	Inhibitory naprawy uszkodzeń DNA w leczeniu raka
GB0419072D0 (en) *	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
TWI375673B (en) *	2005-04-11	2012-11-01	Abbott Lab	1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) *	2005-04-11	2010-06-01	Abbott Laboratories, Inc.	2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
CN101233121A (zh) *	2005-06-10	2008-07-30	彼帕科学公司	Parp调节剂和癌症的治疗
ZA200800907B (en) *	2005-07-18	2010-04-28	Bipar Sciences Inc	Treatment of cancer
US20080293795A1 (en) *	2006-01-17	2008-11-27	Abbott Laboratories	Combination therapy with parp inhibitors
EP1976515A2 (fr) *	2006-01-17	2008-10-08	Abbott Laboratories	Polythérapie faisant appel à des inhibiteurs de la parp
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
JP2010504079A (ja) *	2006-06-12	2010-02-12	バイパーサイエンシズ，インコーポレイティド	Ｐａｒｐ阻害剤を用いる疾病の治療方法
DE102006037399A1 (de) *	2006-08-10	2008-02-14	Archimica Gmbh	Verfahren zur Herstellung von Arylaminen
WO2008030887A2 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Procédés de conception d'inhibiteurs de parp et leurs utilisations
CN101534836B (zh) *	2006-09-05	2011-09-28	彼帕科学公司	Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Traitement du cancer
WO2008030892A2 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Concept de médicament pour inhibiteurs de tubuline, compositions et procédés de traitement
EP2121139B1 (fr) *	2007-01-16	2012-10-10	BiPar Sciences, Inc.	Préparations pour le traitement du cancer

2006
- 2006-06-12 CN CNA2006800276477A patent/CN101233121A/zh active Pending
- 2006-06-12 WO PCT/US2006/022907 patent/WO2006135873A2/fr not_active Ceased
- 2006-06-12 EP EP06772984A patent/EP1904468A4/fr not_active Withdrawn
- 2006-06-12 US US11/423,685 patent/US20070015814A1/en not_active Abandoned
- 2006-06-12 AU AU2006257815A patent/AU2006257815A1/en not_active Abandoned
- 2006-06-12 MX MX2007015479A patent/MX2007015479A/es not_active Application Discontinuation
- 2006-06-12 JP JP2008516030A patent/JP2008543786A/ja active Pending
- 2006-06-12 KR KR1020087000649A patent/KR20080031266A/ko not_active Withdrawn
- 2006-06-12 CA CA002612979A patent/CA2612979A1/fr not_active Abandoned
- 2006-06-12 BR BRPI0611814-3A patent/BRPI0611814A2/pt not_active IP Right Cessation
- 2006-06-12 RU RU2008100017/04A patent/RU2008100017A/ru not_active Application Discontinuation
2007
- 2007-12-04 IL IL187898A patent/IL187898A0/en unknown
2008
- 2008-01-10 NO NO20080176A patent/NO20080176L/no not_active Application Discontinuation
- 2008-12-02 US US12/326,798 patent/US20090076122A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN101233121A (zh)	2008-07-30
WO2006135873A3 (fr)	2007-04-26
KR20080031266A (ko)	2008-04-08
WO2006135873A2 (fr)	2006-12-21
EP1904468A4 (fr)	2009-04-22
EP1904468A2 (fr)	2008-04-02
JP2008543786A (ja)	2008-12-04
RU2008100017A (ru)	2009-07-20
IL187898A0 (en)	2008-03-20
BRPI0611814A2 (pt)	2008-12-09
CA2612979A1 (fr)	2006-12-21
US20090076122A1 (en)	2009-03-19
MX2007015479A (es)	2008-04-09
US20070015814A1 (en)	2007-01-18
AU2006257815A1 (en)	2006-12-21

Legal Events

Date	Code	Title	Description
2012-01-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20080176L (no)	2008-03-10	PARP-modulatorer og behandling av kreft
BR0315381A (pt)	2005-08-23	Composto ou um sal farmaceuticamente aceitável deste, composição farmacêutica, e, métodos para inibir a atividade da enzima dipeptidil peptidase-iv em um mamìfero em necessidade disto, para tratar diabetes em um mamìfero em necessidade disto, para tratar diabete não dependente de insulina (tipo 2) em um mamìfero em necessidade disto, para tratar hiperglicemia em um mamìfero em necessidade disto, para tratar a obesidade em um mamìfero em necessidade disto, para tratar um ou mais distúrbios de lipìdios selecionados do grupo de dislipidemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, hdl baixo e ldl alto em um mamìfero em necessidade disto, e para tratar em um mamìfero em necessidade disto uma ou mais condições
RU2498988C2 (ru)	2013-11-20	Ингибиторы активности протеинтирозинкиназы
NO20080150L (no)	2008-03-10	Inhibitorer av AKT-aktivitet
NO20083013L (no)	2008-09-19	Triazolopyridaziner som tyrosinkinasemodulatorer
NO20073183L (no)	2007-09-17	Tetrahydrokinolinanalgoer som muskariniske agonister
EA200870380A1 (ru)	2009-02-27	Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
BR0315796A (pt)	2005-09-13	Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero
BRPI0417687A (pt)	2007-04-03	derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BRPI0806789B8 (pt)	2021-05-25	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR0306988A (pt)	2004-11-23	Piridazinonas substituìdas como inibidores de p38
NO20084581L (no)	2008-12-12	IAP BIR domene-bindende forbindelser
NZ713361A (en)	2017-06-30	Heat shock protein binding compounds, compositions, and methods for making and using same
NO20055863L (no)	2001-09-12	W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20065984L (no)	2007-02-05	Forbindelser og sammensetninger som PPAR modulatorer
MXPA05010496A (es)	2005-11-16	Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
NO20061194L (no)	2006-05-05	Mitotiske kinesininbibitorer
TW200738234A (en)	2007-10-16	Triazole compounds that modulate HSP90 activity
BR0211122A (pt)	2004-10-26	Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
NO20080141L (no)	2008-01-09	Indanderivater som modulatorer av ionekanaler
WO2008157680A3 (fr)	2009-12-30	Procédés et compositions servant à moduler l'activité de la p300/cbp
NO20072199L (no)	2007-06-05	Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater
NO20082746L (no)	2008-08-08	Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler
BR0212435A (pt)	2004-08-17	Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
WO2006073734A3 (fr)	2007-02-01	Modulateurs de toxicite de l'alpha-synucleine